Brain and Central Nervous System TumorsPhase 2NCT00028795
Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma
A Phase 2 study testing temozolomide, adjuvant therapy and radiation therapy in people with Brain and Central Nervous System Tumors, run by Children's Oncology Group at 230 sites in 7 countries.
Trial summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving chemotherapy together with radiation therapy may kill more tumor cells. Read more about this study
- Who is it for?
- Ages 3 to 21 years
- Conditions the study is for
- Brain and Central Nervous System Tumors
- What is being tested?
- temozolomide, adjuvant therapy and radiation therapy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 170 participants
- Where
- 230 sitesin 7 countries
- Study dates
- Dec 2002to Mar 2012
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 to 21 years
- All sexes
- No healthy volunteers
- Child, Adult
DISEASE CHARACTERISTICS:
- Histologically confirmed newly diagnosed CNS tumor of the following types:
- High grade glioma (HGG) of one of the following histologies:
- Anaplastic astrocytoma (grade III)
- Glioblastoma multiforme (grade IV)
- Gliosarcoma
- Primary spinal cord malignant glioma
- Diffuse intrinsic pontine glioma (DIPG)
- Diagnosed by gadolinium-enhanced MRI
- At least 2/3 of tumor situated in the pons AND tumor clearly originated in the pons
- No diffuse leptomeningeal disease
- No tumors with features not typical of diffuse intrinsic brainstem glioma, including any of the following:
- Dorsally exophytic brainstem glioma
- Cervico-medullary junction tumor
- Focal low-grade glioma of the midbrain or brainstem
- No diffuse brainstem enlargement due to neurofibromatosis
- No primary brain stem malignant glioma
- No M+ disease (CSF positive for tumor or metastatic disease)
- Must begin study radiotherapy within 6 weeks after surgical resection (for HGG patients) or diagnosis (for DIPG patients)
PATIENT CHARACTERISTICS:
Age:
- 3 to 21
Performance status:
- Karnofsky 50-100% OR
- Lansky 50-100%
Life expectancy:
- At least 2 months
Hematopoietic:
- Absolute neutrophil count at least 1,000/mm^3
- Platelet count at least 100,000/mm^3*
- Hemoglobin at least 10.0 g/dL* NOTE: *Transfusion independent
Hepatic:
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- SGOT or SGPT less than 2.5 times ULN
Renal:
- Creatinine no greater than 1.5 times ULN
Other:
- No other concurrent malignancy
- Concurrent seizure disorder allowed if well controlled on anticonvulsants
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 2 months after completion of study treatment
PRIOR CONCURRENT THERAPY:
Biologic:
- No concurrent routine cytokine support
Chemotherapy:
- Not specified
Endocrine therapy:
- No concurrent corticosteroids except for increased intracranial pressure in patients with CNS tumors
Radiotherapy:
- See Disease Characteristics
Surgery:
- See Disease Characteristics
Other:
- No prior therapy for HGG or DIPG
Trial locations and contacts
230 sites in 7 countries.
230 sites in 7 countries
United States202 sites
Children's Hospital Medical Center of Akron
Akron, Ohio, 44308-1062
Children's Hospital at Albany Medical Center
Albany, New York, 12208
University of New Mexico Cancer Research and Treatment Center
Albuquerque, New Mexico, 87131
Texas Tech University Health Sciences Center School of Medicine
Amarillo, Texas, 79106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0914
Mission Hospitals - Memorial Campus
Asheville, North Carolina, 28801
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus
Atlanta, Georgia, 30342
MBCCOP-Medical College of Georgia Cancer Center
Augusta, Georgia, 30912-4000
Children's Hospital of Austin
Austin, Texas, 78701
Greenebaum Cancer Center at University of Maryland Medical Center
Baltimore, Maryland, 21201-1595
Alvin and Lois Lapidus Cancer Institute at Sinai Hospital
Baltimore, Maryland, 21215
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231-7223
Pediatric Specialty Clinic at Eastern Maine Medical Center
Bangor, Maine, 04401
Comprehensive Cancer Center at University of Alabama at Birmingham
Birmingham, Alabama, 35233
St. Luke's Mountain States Tumor Institute - Boise
Boise, Idaho, 83712
Floating Hospital for Children
Boston, Massachusetts, 02111
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
Boston, Massachusetts, 02115
Brooklyn Hospital Center
Brooklyn, New York, 11201-5493
SUNY Downstate Medical Center
Brooklyn, New York, 11203
Brookdale University Hospital and Medical Center
Brooklyn, New York, 11212
Comprehensive Cancer Center at Maimonides Medical Center
Brooklyn, New York, 11219
Vermont Cancer Center at University of Vermont
Burlington, Vermont, 05401-3498
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
Chapel Hill, North Carolina, 27599
Hollings Cancer Center at Medical University of South Carolina
Charleston, South Carolina, 29425-0721
West Virginia University - Robert C. Byrd Health Sciences Center - Charleston Division
Charleston, West Virginia, 25302
Blumenthal Cancer Center at Carolinas Medical Center
Charlotte, North Carolina, 28232-2861
Presbyterian Cancer Center at Presbyterian Hospital
Charlotte, North Carolina, 28233
University of Virginia Cancer Center
Charlottesville, Virginia, 22908
University of Chicago Cancer Research Center
Chicago, Illinois, 60601
Rush University Medical Center
Chicago, Illinois, 60612
University of Illinois Medical Center
Chicago, Illinois, 60612
Children's Memorial Hospital - Chicago
Chicago, Illinois, 60614
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229-3039
Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University
Cleveland, Ohio, 44106-5065
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
University of Missouri - Columbia
Columbia, Missouri, 65203
Palmetto Health South Carolina Cancer Center
Columbia, South Carolina, 29203
Columbus Children's Hospital
Columbus, Ohio, 43205-2696
Medical City Dallas Hospital
Dallas, Texas, 75230
Simmons Cancer Center at University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, 75390-9063
Geisinger Medical Center
Danville, Pennsylvania, 17822-1320
Children's Medical Center - Dayton
Dayton, Ohio, 45404
Children's Hospital Cancer Center
Denver, Colorado, 80218
Presbyterian - St. Luke's Medical Center
Denver, Colorado, 80218
Blank Children's Hospital
Des Moines, Iowa, 50309
Children's Hospital of Michigan
Detroit, Michigan, 48201
Van Elslander Cancer Center at St. John Hospital and Medical Center
Detroit, Michigan, 48236
Southern California Permanente Medical Group
Downey, California, 90242
City of Hope Comprehensive Cancer Center
Duarte, California, 91010-3000
St. Mary's - Duluth Clinic Cancer Center
Duluth, Minnesota, 55805
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
INOVA Fairfax Hospital
Falls Church, Virginia, 22042-3300
Dakota Cancer Institute at Innovis Health - Dakota Clinic
Fargo, North Dakota, 58103-4940
Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
Farmington, Connecticut, 06360-7106
Hurley Medical Center
Flint, Michigan, 48503
Broward General Medical Center
Fort Lauderdale, Florida, 33316
Children's Hospital of Southwest Florida
Fort Myers, Florida, 33908
Cook Children's Medical Center - Fort Worth
Fort Worth, Texas, 76104
University of Florida Shands Cancer Center
Gainesville, Florida, 32610-0296
University of Texas Medical Branch
Galveston, Texas, 77555-0209
DeVos Children's Hospital
Grand Rapids, Michigan, 49503
Bellin Memorial Hospital
Green Bay, Wisconsin, 54301
CCOP - St. Vincent Hospital Cancer Center, Green Bay
Green Bay, Wisconsin, 54301
St. Vincent Hospital
Green Bay, Wisconsin, 54307-9070
Leo W. Jenkins Cancer Center at Pitt County Memorial Hospital
Greenville, North Carolina, 27858-4354
Children's Hospital of Greenville Hospital System
Greenville, South Carolina, 29605
Hackensack University Medical Center
Hackensack, New Jersey, 07601
Penn State Children's Hospital
Hershey, Pennsylvania, 17033
Joe DiMaggio Children's Hospital at Memorial
Hollywood, Florida, 33021
Cancer Research Center of Hawaii
Honolulu, Hawaii, 96813
Tripler Army Medical Center
Honolulu, Hawaii, 96859-5000
M.D. Anderson Cancer Center at University of Texas
Houston, Texas, 77030-4009
Baylor College of Medicine
Houston, Texas, 77030
Cabell Huntington Hospital
Huntington, West Virginia, 25701
Riley Children Cancer Center at Riley Hospital for Children
Indianapolis, Indiana, 46202-5225
St. Vincent Hospitals and Health Care Centers
Indianapolis, Indiana, 46260
Holden Comprehensive Cancer Center at University of Iowa
Iowa City, Iowa, 52242-1009
University of Mississippi Medical Center
Jackson, Mississippi, 39216-4505
Nemours Children's Clinic
Jacksonville, Florida, 32207
East Tennessee State University Cancer Center at Johnson City Medical Center
Johnson City, Tennessee, 37614-0622
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007-5364
Children's Mercy Hospital
Kansas City, Missouri, 64108
East Tennessee Children's Hospital
Knoxville, Tennessee, 37901
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
Rebecca and John Moores UCSD Cancer Center
La Jolla, California, 92093-0658
San Antonio Military Pediatric Cancer and Blood Disorders Center
Lackland Air Force Base, Texas, 78236
Breslin Cancer Center at Ingham Regional Medical Center
Lansing, Michigan, 48910
Nevada Cancer Research Foundation
Las Vegas, Nevada, 89109
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756
Markey Cancer Center at University of Kentucky Chandler Medical Center
Lexington, Kentucky, 40536-0284
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Loma Linda University Cancer Institute at Loma Linda University Medical Center
Loma Linda, California, 92354
Jonathan Jaques Children's Cancer Center at Miller Children's Hospital
Long Beach, California, 90801-1428
Children's Hospital Los Angeles
Los Angeles, California, 90027-0700
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center
Los Angeles, California, 90048
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California, 90095-1781
Kosair Children's Hospital
Louisville, Kentucky, 40202-3830
Covenant Children's Hospital
Lubbock, Texas, 79410
Medical Center of Central Georgia
Macon, Georgia, 31201
Children's Hospital Central California
Madera, California, 93638-8762
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, 53792-6164
Marshfield Clinic - Marshfield Center
Marshfield, Wisconsin, 54449-5772
CCOP - Marshfield Clinic Research Foundation
Marshfield, Wisconsin, 54449
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105
Jackson Memorial Hospital
Miami, Florida, 33136
Miami Children's Hospital
Miami, Florida, 33155
Baptist-South Miami Regional Cancer Program
Miami, Florida, 33176-2197
Midwest Children's Cancer Center
Milwaukee, Wisconsin, 53226
Children's Hospitals and Clinics - Minneapolis/St. Paul
Minneapolis, Minnesota, 55404
University of South Alabama Cancer Research Institute
Mobile, Alabama, 36604
Mary Babb Randolph Cancer Center at West Virginia University Hospitals
Morgantown, West Virginia, 26506-9300
Vanderbilt Children's Hospital
Nashville, Tennessee, 37232-6310
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
New Brunswick, New Jersey, 08903
Yale Comprehensive Cancer Center
New Haven, Connecticut, 06520-8064
Schneider Children's Hospital
New Hyde Park, New York, 11040
MBCCOP - LSU Health Sciences Center
New Orleans, Louisiana, 70112
Tulane Cancer Center at Tulane University Hospital and Clinic
New Orleans, Louisiana, 70112
Children's Hospital of New Orleans
New Orleans, Louisiana, 70118
Ochsner Cancer Institute at Ochsner Clinic Foundation
New Orleans, Louisiana, 70121
Memorial Sloan-Kettering Cancer Center
New York, New York, 10021
New York Weill Cornell Cancer Center at Cornell University
New York, New York, 10021
Mount Sinai Medical Center
New York, New York, 10029
Herbert Irving Comprehensive Cancer Center at Columbia University
New York, New York, 10032
Newark Beth Israel Medical Center
Newark, New Jersey, 07112-2094
Children's Hospital of the King's Daughters
Norfolk, Virginia, 23507
Advocate Hope Children's Hospital
Oak Lawn, Illinois, 60453
Children's Hospital and Research Center at Oakland
Oakland, California, 94609-1809
Children's Hospital at Oklahoma University Medical Center
Oklahoma City, Oklahoma, 73104
Children's Hospital of Omaha
Omaha, Nebraska, 68114
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
Omaha, Nebraska, 68198-2168
Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
Orange, California, 92868
Children's Hospital of Orange County
Orange, California, 92868
Florida Hospital Cancer Institute
Orlando, Florida, 32804
Nemours Children's Clinic-Orlando
Orlando, Florida, 32806
Lucile Packard Children's Hospital at Stanford University Medical Center
Palo Alto, California, 94304
Lutheran General Cancer Care Center
Park Ridge, Illinois, 60068-1174
St. Joseph's Hospital and Medical Center
Paterson, New Jersey, 07503
Sacred Heart Children's Hospital
Pensacola, Florida, 32504
Saint Jude Midwest Affiliate
Peoria, Illinois, 61637
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
St. Christopher's Hospital for Children
Philadelphia, Pennsylvania, 19134-1095
Phoenix Children's Hospital
Phoenix, Arizona, 85016
Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15213
CCOP - Columbia River Oncology Program
Portland, Oregon, 97225
Legacy Emanuel Hospital and Health Center & Children's Hospital
Portland, Oregon, 97227
Doernbecher Children's Hospital at Oregon Health & Science University
Portland, Oregon, 97239-3098
Naval Medical Center - Portsmouth
Portsmouth, Virginia, 23708-5100
Rhode Island Hospital
Providence, Rhode Island, 02903
Massey Cancer Center at Virginia Commonwealth University
Richmond, Virginia, 23298-0121
Carilion Medical Center for Children at Roanoke Community Hospital
Roanoke, Virginia, 24029
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
James P. Wilmot Cancer Center at University of Rochester Medical Center
Rochester, New York, 14642
William Beaumont Hospital - Royal Oak Campus
Royal Oak, Michigan, 48073-6769
Sutter Cancer Center
Sacramento, California, 95816
University of California Davis Cancer Center
Sacramento, California, 95817
Kaiser Permanente Medical Center - Sacramento
Sacramento, California, 95825
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, 84112
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78207
MBCCOP - South Texas Pediatrics
San Antonio, Texas, 78229-3900
Methodist Cancer Center at Methodist Specialty and Transplant Hospital
San Antonio, Texas, 78229-3902
Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego
San Diego, California, 92120
Children's Hospital and Health Center - San Diego
San Diego, California, 92123-4282
UCSF Comprehensive Cancer Center
San Francisco, California, 94143
Santa Barbara Cottage Hospital
Santa Barbara, California, 93102
Kaiser Permanente Medical Center - Santa Clara Kiely Campus
Santa Clara, California, 95051-5386
Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center
Savannah, Georgia, 31405
Maine Children's Cancer Program
Scarborough, Maine, 04074-9308
Children's Hospital and Regional Medical Center - Seattle
Seattle, Washington, 98105
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109-1024
Group Health Central Hospital
Seattle, Washington, 98112
Walter Reed Army Medical Center
Silver Spring, Maryland, 20910
Avera Cancer Institute
Sioux Falls, South Dakota, 57105-1080
Sioux Valley Hospital and University of South Dakota Medical Center
Sioux Falls, South Dakota, 57117-5039
Deaconess Medical Center
Spokane, Washington, 99210-0248
Southern Illinois University School of Medicine
Springfield, Illinois, 62794-9658
Baystate Regional Cancer Program at D'Amour Center for Cancer Care
Springfield, Massachusetts, 01107
Cardinal Glennon Children's Hospital
St Louis, Missouri, 63104
St. Louis Children's Hospital
St Louis, Missouri, 63110
All Children's Hospital
St. Petersburg, Florida, 33701
Long Island Cancer Center at Stony Brook University Hospital
Stony Brook, New York, 11794-8174
Valerie Fund Children's Center at Atlantic Health
Summit, New Jersey, 07901
SUNY Upstate Medical University Hospital
Syracuse, New York, 13210
Mary Bridge Children's Hospital and Health Center - Tacoma
Tacoma, Washington, 98415-0299
Madigan Army Medical Center
Tacoma, Washington, 98431-0001
St. Joseph's Children's Hospital of Tampa
Tampa, Florida, 33677-4227
CCOP - Scott and White Hospital
Temple, Texas, 76508
Center for Cancer Prevention and Care at Scott and White Clinic
Temple, Texas, 76508
Albert Einstein Cancer Center at Albert Einstein College of Medicine
The Bronx, New York, 10461
Toledo Children's Hospital
Toledo, Ohio, 43601
St. Vincent Mercy Medical Center
Toledo, Ohio, 43608
General Robert Huyser Cancer Center at David Grant Medical Center
Travis Air Force Base, California, 94535
Arizona Cancer Center at University of Arizona Health Sciences Center
Tucson, Arizona, 85724
Natalie Warren Bryant Cancer Center at St. Francis Hospital
Tulsa, Oklahoma, 74136
New York Medical College
Valhalla, New York, 10595
Lombardi Cancer Center at Georgetown University Medical Center
Washington D.C., District of Columbia, 20007
Children's National Medical Center
Washington D.C., District of Columbia, 20010-2970
Kaplan Cancer Center at St. Mary's Medical Center
West Palm Beach, Florida, 33407
Wesley Medical Center
Wichita, Kansas, 67214
Alfred I. duPont Hospital for Children
Wilmington, Delaware, 19899
Comprehensive Cancer Center at Wake Forest University
Winston-Salem, North Carolina, 27157-1081
UMASS Memorial Cancer Center - University Campus
Worcester, Massachusetts, 01655
Tod Children's Hospital - Forum Health
Youngstown, Ohio, 44501
Canada15 sites
Alberta Children's Hospital
Calgary, Alberta, T2T 5C7
Cross Cancer Institute at University of Alberta
Edmonton, Alberta, T6G 1Z2
IWK Health Centre
Halifax, Nova Scotia, B3J 3G9
McMaster Children's Hospital at Hamilton Health Sciences
Hamilton, Ontario, L8S 4J9
Children's Hospital of Western Ontario
London, Ontario, N6C 2V5
Montreal Children's Hospital at McGill University Health Center
Montreal, Quebec, H3G 1A4
Hopital Sainte Justine
Montreal, Quebec, H3T 1C5
Children's Hospital of Eastern Ontario
Ottawa, Ontario, K1H 8L1
Allan Blair Cancer Centre at Pasqua Hospital
Regina, Saskatchewan, S4T 7T1
Centre de Recherche du Centre Hospitalier de l'Universite Laval
Sainte-Foy, Quebec, GIV 4G2
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4
Janeway Children's Health and Rehabilitation Centre
St. John's, Newfoundland and Labrador, A1B 3V6
Hospital for Sick Children
Toronto, Ontario, M5G 1X8
British Columbia Children's Hospital
Vancouver, British Columbia, V6H 3V4
CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9
Australia6 sites
Royal Children's Hospital
Brisbane, Queensland, 4029
Women's and Children's Hospital
North Adelaide, South Australia, 5006
Royal Children's Hospital
Parkville, Victoria, 3052
Princess Margaret Hospital for Children
Perth, Western Australia, 6001
Sydney Children's Hospital
Randwick, New South Wales, 2031
Children's Hospital at Westmead
Westmead, New South Wales, 2145
Switzerland3 sites
Swiss Pediatric Oncology Group Bern
Bern, CH 3010
Swiss Pediatric Oncology Group Geneva
Geneva, CH 1211
Swiss Pediatric Oncology Group Lausanne
Lausanne, CH 1011
Puerto Rico2 sites
Puerto Rico Cancer Center at University of Puerto Rico - Medical Sciences Campus
San Juan, 00936-5067
San Jorge Children's Hospital
Santurce, 00912
About this study
Official title: A Phase II Study of Temozolomide in the Treatment of Children With High Grade Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving chemotherapy together with radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving chemotherapy together with radiation therapy after surgery followed by chemotherapy alone works in children with newly diagnosed astrocytoma, glioblastoma multiforme, gliosarcoma, or diffuse intrinsic pontine glioma.
Read the detailed description
OBJECTIVES:
- Compare the event-free survival of patients with newly diagnosed anaplastic astrocytoma, glioblastoma multiforme, gliosarcoma, or diffuse intrinsic pontine glioma (DIPG) treated with adjuvant temozolomide administered concurrently with postoperative radiotherapy and then alone as maintenance therapy vs historical control cohorts treated in prior Pediatric Oncology Group and Children's Cancer Group studies.
- Determine the toxicity of this regimen in these patients.
- Determine the efficacy of this regimen in patients with DIPG.
- Determine the toxicity of this regimen in patients with DIPG.
OUTLINE: This is a multicenter study.
- Adjuvant chemoradiotherapy: Beginning within 6 weeks after surgical resection or diagnosis*, patients without gross residual disease undergo cranial irradiation 5 days a week for 6 weeks. Beginning within 6 weeks after surgical resection, patients with gross residual disease undergo radiotherapy as above followed by boost radiotherapy for 1 week. All patients receive oral temozolomide once daily beginning within 5 days after initiation of radiotherapy and continuing for a total of 6 weeks in the absence of disease progression or unacceptable toxicity.
- Adjuvant maintenance therapy: Beginning 4 weeks after completion of adjuvant chemoradiotherapy, patients receive oral temozolomide on days 1-5. Treatment repeats every 28 days for a total of 10 courses in the absence of disease progression or unacceptable toxicity.
NOTE: *For patients with diffuse intrinsic pontine glioma only
Patients are followed every 3-6 months for 4 years and then annually thereafter.
PROJECTED ACCRUAL: A total of 50-60 patients will be accrued for this study within 12-14 months.
- Conditions
- Brain and Central Nervous System Tumors
- Being tested
- temozolomide, adjuvant therapy, radiation therapy
- Keywords
- childhood brain stem glioma, childhood high-grade cerebral astrocytoma, childhood spinal cord neoplasm, untreated childhood brain stem glioma
- Medical subject headings
- Central Nervous System Neoplasms, Astrocytoma, Spinal Cord Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
temozolomideDrug
adjuvant therapyProcedure or surgery
radiation therapyRadiation
| Study group | Role | What they receive |
|---|---|---|
| Chemoradiotherapy | Experimental | Not described Receives: Drug: temozolomide; Procedure: adjuvant therapy; Radiation: radiation therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Improved outcome
Toxicity as assessed by NCI CTCAE v. 2.0
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2003 (estimated)
- Study startDec 2002
- Primary completionSep 2007
- Study completionMar 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Brain and Central Nervous System TumorsStudies of the same condition, open and under way.
- More trials run by Children's Oncology GroupThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 170 participants (actual)
Sponsor and investigators
- Lead sponsor
- Children's Oncology Group
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Kenneth J. Cohen, MD, MBA, Study chair, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00028795
- Sponsor's protocol ID
- ACNS0126
- Other IDs
- COG-ACNS0126, CDR0000069135
- Status last verified
- Feb 2014
- First submitted
- 4 Jan 2002
- Last updated
- 21 Feb 2014
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Pollack IF, Hamilton RL, Burger PC, Brat DJ, Rosenblum MK, Murdoch GH, Nikiforova MN, Holmes EJ, Zhou T, Cohen KJ, Jakacki RI; Children's Oncology Group. Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group. J Neurooncol. 2010 Sep;99(2):155-63. doi: 10.1007/s11060-010-0297-3. Epub 2010 Jul 4.
PubMed 20607350Pollack IF, Hamilton RL, Sobol RW, Nikiforova MN, Nikiforov YE, Lyons-Weiler MA, LaFramboise WA, Burger PC, Brat DJ, Rosenblum MK, Gilles FH, Yates AJ, Zhou T, Cohen KJ, Finlay JL, Jakacki RI; Children's Oncology Group. Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 Dec 1;55(6):1066-71. doi: 10.1002/pbc.22634.
PubMed 20589656Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey RS, Bouffet E, Pollack IF. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol. 2011 Apr;13(4):410-6. doi: 10.1093/neuonc/noq205. Epub 2011 Feb 22.
PubMed 21345842Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, Brat DJ, Rosenblum MK, Hamilton RL, Lavey RS, Heideman RL. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol. 2011 Mar;13(3):317-23. doi: 10.1093/neuonc/noq191.
PubMed 21339192Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. doi: 10.1002/cncr.22961.
PubMed 17705175
Study at a glance
From the registry record, last updated by the sponsor on 21 Feb 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II Study of Temozolomide in the Treatment of Children With High Grade Glioma
- ClinicalTrials.gov ID
- NCT00028795
- Acronym / sponsor ID
- ACNS0126
- Conditions
- Brain and Central Nervous System Tumors
- Keywords
- childhood brain stem glioma, childhood high-grade cerebral astrocytoma, childhood spinal cord neoplasm, untreated childhood brain stem glioma
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 170 participants (actual)
- Lead sponsor
- Children's Oncology GroupResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- Dec 2002
- Primary completion
- Sep 2007 (actual)
- Study completion
- Mar 2012 (actual)
- First posted
- 27 Jan 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving chemotherapy together with radiation therapy may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving chemotherapy together with radiation therapy after surgery followed by chemotherapy alone works in children with newly diagnosed astrocytoma, glioblastoma multiforme, gliosarcoma, or diffuse intrinsic pontine glioma.
Detailed description
OBJECTIVES:
- Compare the event-free survival of patients with newly diagnosed anaplastic astrocytoma, glioblastoma multiforme, gliosarcoma, or diffuse intrinsic pontine glioma (DIPG) treated with adjuvant temozolomide administered concurrently with postoperative radiotherapy and then alone as maintenance therapy vs historical control cohorts treated in prior Pediatric Oncology Group and Children's Cancer Group studies.
- Determine the toxicity of this regimen in these patients.
- Determine the efficacy of this regimen in patients with DIPG.
- Determine the toxicity of this regimen in patients with DIPG.
OUTLINE: This is a multicenter study.
- Adjuvant chemoradiotherapy: Beginning within 6 weeks after surgical resection or diagnosis*, patients without gross residual disease undergo cranial irradiation 5 days a week for 6 weeks. Beginning within 6 weeks after surgical resection, patients with gross residual disease undergo radiotherapy as above followed by boost radiotherapy for 1 week. All patients receive oral temozolomide once daily beginning within 5 days after initiation of radiotherapy and continuing for a total of 6 weeks in the absence of disease progression or unacceptable toxicity.
- Adjuvant maintenance therapy: Beginning 4 weeks after completion of adjuvant chemoradiotherapy, patients receive oral temozolomide on days 1-5. Treatment repeats every 28 days for a total of 10 courses in the absence of disease progression or unacceptable toxicity.
NOTE: *For patients with diffuse intrinsic pontine glioma only
Patients are followed every 3-6 months for 4 years and then annually thereafter.
PROJECTED ACCRUAL: A total of 50-60 patients will be accrued for this study within 12-14 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Chemoradiotherapy | Experimental | Drug: temozolomide, Procedure: adjuvant therapy, Radiation: radiation therapy |
Who may qualify
- Ages
- 3 to 21 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| temozolomide | Drug | Chemoradiotherapy |
| adjuvant therapy | Procedure or surgery | Chemoradiotherapy |
| radiation therapy | Radiation | Chemoradiotherapy |
Primary outcome
Improved outcome
Toxicity as assessed by NCI CTCAE v. 2.0
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Feb 2014.
- Background: PubMed 20607350Pollack IF, Hamilton RL, Burger PC, Brat DJ, Rosenblum MK, Murdoch GH, Nikiforova MN, Holmes EJ, Zhou T, Cohen KJ, Jakacki RI; Children's Oncology Group. Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group. J Neurooncol. 2010 Sep;99(2):155-63. doi: 10.1007/s11060-010-0297-3. Epub 2010 Jul 4.
- Background: PubMed 20589656Pollack IF, Hamilton RL, Sobol RW, Nikiforova MN, Nikiforov YE, Lyons-Weiler MA, LaFramboise WA, Burger PC, Brat DJ, Rosenblum MK, Gilles FH, Yates AJ, Zhou T, Cohen KJ, Finlay JL, Jakacki RI; Children's Oncology Group. Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 Dec 1;55(6):1066-71. doi: 10.1002/pbc.22634.
- Results publication: PubMed 21345842Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey RS, Bouffet E, Pollack IF. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol. 2011 Apr;13(4):410-6. doi: 10.1093/neuonc/noq205. Epub 2011 Feb 22.
- Results publication: PubMed 21339192Cohen KJ, Pollack IF, Zhou T, Buxton A, Holmes EJ, Burger PC, Brat DJ, Rosenblum MK, Hamilton RL, Lavey RS, Heideman RL. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol. 2011 Mar;13(3):317-23. doi: 10.1093/neuonc/noq191.
- Results publication: PubMed 17705175Nicholson HS, Kretschmar CS, Krailo M, Bernstein M, Kadota R, Fort D, Friedman H, Harris MB, Tedeschi-Blok N, Mazewski C, Sato J, Reaman GH. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer. 2007 Oct 1;110(7):1542-50. doi: 10.1002/cncr.22961.
Related trials for Brain and Central Nervous System Tumors
RecruitingPhase 2
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
Triple-Negative Breast Cancer (TNBC), Brain Metastases
Active, not recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
RecruitingPhase 1/2
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Glioma, Medulloblastoma
Recruiting
Virtual Home-based Exercise Intervention (RISE) to Improve Cancer-Related Cognitive Impairment and Gut Microbiome in Adolescent and Young Adult Brain Tumor Survivors
Cancer-related Cognitive Dysfunction, Primary Brain Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kenneth J. Cohen, MD, MBA study chair
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
230 sites in 7 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing temozolomide, adjuvant therapy and radiation therapy in people with Brain and Central Nervous System Tumors, run by Children's Oncology Group at 230 sites in 7 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Feb 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 230 sites in United States, Canada, Australia, Switzerland, Puerto Rico and 2 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Improved outcome. The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00028795, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Feb 2014.